Showing results (11-20 of 29) with videos related to
Sort By:
Pageof 3
American Journal of Physiology. Lung Cellular and Molecular Physiology|February 8, 2011
Alternaria alternata serine proteases induce lung inflammation and airway epithelial cell activation via PAR2Scott Boitano, Andrea N Flynn, Cara L Sherwood, et al.The Journal of Biological Chemistry|April 7, 2011
The protease-activated receptor-2-specific agonists 2-aminothiazol-4-yl-LIGRL-NH2 and 6-aminonicotinyl-LIGRL-NH2 stimulate multiple signaling pathways to induce physiological responses in vitro and in vivoAndrea N Flynn, Dipti V Tillu, Marina N Asiedu, et al.Bioconjugate Chemistry|September 22, 2012
Lanthanide labeling of a potent protease activated receptor-2 agonist for time-resolved fluorescence analysisJustin Hoffman, Andrea N Flynn, Dipti V Tillu, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|November 24, 2011
Validation of a clinical score for assessing the risk of resistant pathogens in patients with pneumonia presenting to the emergency departmentAndrew F Shorr, Marya D Zilberberg, Richard Reichley, et al.Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|May 17, 2013
Readmission following hospitalization for pneumonia: the impact of pneumonia type and its implication for hospitalsAndrew F Shorr, Marya D Zilberberg, Richard Reichley, et al.Anti-Cancer Drugs|March 16, 2019
Talazoparib has no clinically relevant effect on QTc interval in patients with advanced solid tumorsJustin Hoffman, Jayeta Chakrabarti, Anna Plotka, et al.Clinical Imaging|June 29, 2021
Anti-NMDA receptor encephalitis and brain atrophy in children and adults: A quantitative studyFrederick C Bassal, Matthew Harwood, Ann Oh, et al.Journal of Pharmacokinetics and Pharmacodynamics|June 4, 2026
Exposure-safety analyses of talazoparib in combination with enzalutamide in patients with metastatic castration-resistant prostate cancer (mCRPC) in the TALAPRO-2 trialYibo Wang, Mark Hadigol, Victor Ruberio Lincha, et al.CPT: Pharmacometrics & Systems Pharmacology|December 11, 2025
Talazoparib Formulation Bridging in Cancer Patients-Challenges and the Critical Role of Model-Informed Drug Development in Approval Despite Failed BioequivalenceDiane Wang, Cathy Cen Guo, Xizhe Gao, et al.Clinical Pharmacokinetics|March 9, 2021
The Effect of Renal Impairment on the Pharmacokinetics and Safety of Talazoparib in Patients with Advanced Solid TumorsChandrasekar Durairaj, Jayeta Chakrabarti, Cristiano Ferrario, et al.Pageof 3